Efficacy of tirofiban sequential DAPT in the treatment of perforator atherosclerosis

Efficacy and prognostic associate factors of tirofiban sequential DAPT in the treatment of perforator atherosclerotic disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062760

Enrollment

Unknown

Registered

2022-08-18

Start date

2022-08-18

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perforator atherosclerotic disease

Interventions

Research Group:Tirofiban sequential dual antiplatelet

The control group:Dual antiplatelet

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. It met the diagnostic criteria for perforator artery atherosclerosis (BAD), according to the 2021 Chinese Expert Consensus on Perforator artery Atherosclerosis; 2. Aged 18-75 years; 3. Within 72 hours of onset 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe heart, lung, liver and renal dysfunction; 2. diseases prone to bleeding; 3. Complicated with infectious diseases; 4. autoimmune diseases, gout, etc.; 5. Previous stroke history, and mRS score >1 before onset; 6. Other researchers think it is not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Modified Rankin score;	—

Secondary

Measure	Time frame
National Institutes of Health Stroke Scale(NIHSS) score;Barthel index(BI) score;Serum inflammatory factor;	—

Countries

China

Contacts

Public ContactPing Chen

Department of Neurology, the First Hospital of Putian

edmunc@sina.com+86 15960523537

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026